HFA
CARM

Hoover Financial Advisors’s Carisma Therapeutics CARM Stock Holding History

Hoover Financial Advisors’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$2K Hold
26
– – ﹤0.01% 589
2021
Q1 		$1K Buy
+26
New +$1.23K ﹤0.01% 553

Other funds holding CARM

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TG
TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Hoover Financial Advisors's CARM Position: Q2 2021 in Review

Hoover Financial Advisors held its Carisma Therapeutics (CARM) position steady in Q2 2021 at 26 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #589.

Hoover Financial Advisors first reported a position in CARM in Q1 2021 and has held it in 2 quarters since. 105 funds tracked by Wall St. Rank hold CARM as of Q2 2021.

  • Hoover Financial Advisors held 26 shares of Carisma Therapeutics worth $2K as of Q2 2021.
  • Hoover Financial Advisors left its Carisma Therapeutics share count unchanged in Q2 2021.
  • Carisma Therapeutics made up ﹤0.01% of Hoover Financial Advisors's portfolio in Q2 2021, its #589 holding.
  • Hoover Financial Advisors first reported a position in Carisma Therapeutics in Q1 2021 and has held it in 2 quarters since.
  • 105 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q2 2021.

Based on Hoover Financial Advisors's 13F filing for Q2 2021, filed 28 Jul 2021.